Results 191 to 200 of about 1,955 (223)
Some of the next articles are maybe not open access.
Burosumab treatment for fibrous dysplasia
Bone, 2021Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) is a rare mosaic disorder of Gαs activation. Fibroblast Growth Factor 23 (FGF23)-mediated hypophosphatemia is a feature of FD/MAS that has been associated with poor skeletal outcomes. Standard therapy includes oral phosphorus and vitamin D analogs; however, treatment is limited by potential adverse ...
Anne, Gladding +3 more
openaire +2 more sources
Appropriate dosing of burosumab in tumor-induced osteomalacia
Osteoporosis International, 2022We appreciated the recently published paper of Crotti and coworkers in which the authors reported a patient with tumor-induced osteomalacia (TIO) treated with burosumab for over 2 years for a tumor located in the pre-sacral region that recurred 18 months after excision.
Colangelo, Luciano +4 more
openaire +3 more sources
Burosumab for Pediatric X-Linked Hypophosphatemia
Current Osteoporosis Reports, 2021X-Linked hypophosphatemia (XLH) is the most common genetic cause of rickets. This review describes advances in the management of XLH using burosumab which was FDA approved for treating children with XLH in 2018.Elevated FGF23 in XLH leads to systemic hypophosphatemia and several musculoskeletal manifestations, including rachitic bone deformities ...
openaire +2 more sources
Burosumab in tumor-induced osteomalacia: A case report
Joint Bone Spine, 2020Tumor-induced osteomalacia is a rare cause of acquired hypophosphatemia due to the paraneoplastic overproduction of fibroblast growth factor-23. Unlike many causes of osteomalacia, tumor-induced osteomalacia is curable by resection of the offending tumor.
Alvin Lee Day +3 more
openaire +2 more sources
Burosumab: First Global Approval
Drugs, 2018Burosumab (Crysvita®; Kyowa Hakko Kirin Co., Ltd. and Ultragenyx Pharmaceutical Inc.) is a fully human monoclonal antibody directed at fibroblast growth factor 23 (FGF23). Excessive FGF23 production has been implicated in various hypophosphataemic diseases. Inhibition of FGF23 by burosumab results in increased renal phosphate reabsorption and increased
openaire +2 more sources
Efficacy and Safety of Burosumab in X-linked Hypophosphatemia
The Journal of Clinical Endocrinology & Metabolism, 2023Abstract Context Burosumab is approved for the treatment of X-linked hypophosphatemia (XLH). Objective To assess the efficacy and safety of burosumab in XLH patients, we conducted a systematic review and meta-analysis.
Sen Wang +5 more
openaire +2 more sources
Efficacité du burosumab dans un cas d'ostéomalacie oncogénique
Revue du Rhumatisme, 2020Resume L’osteomalacie oncologique est une cause rare d’hypophosphatemie acquise induite par une surexpression paraneoplasique de FGF-23. A l’inverse de nombreuses causes de l’osteomalacie, la TIO est une maladie curable par excision chirurgicale de la tumeur responsable.
Alvin Lee Day +3 more
openaire +1 more source
Burosumab: Current status and future prospects
Best Practice & Research Clinical Endocrinology & MetabolismHypophosphatemic rickets/osteomalacia caused by FGF23 excess is conventionally treated with multiple doses of inorganic phosphate salts and active vitamin D analogs. However, conventional therapy targets the consequences of elevated FGF23 and not the elevated FGF23 itself and is associated with poor adherence and long-term complications such as ...
Alpesh, Goyal, Nikhil, Tandon
openaire +2 more sources
Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire +1 more source